Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States: Supplementary Data

Name: Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States: Supplementary Data
Creator: Yasser Albogami
Published: 2020-04-08T18:15:48.574Z
Keywords: Dermatology, Pharmacoepidemiology, Drug Safety, Clinical Risk Management

Albogami, Yasser; Sarayani, Amir; Hincapie-Castillo, Juan; Winterstein, Almut

doi:10.17632/6gdm5j3fjb.2

Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States: Supplementary Data

Published: 8 April 2020| Version 2 | DOI: 10.17632/6gdm5j3fjb.2

Contributors:

Yasser Albogami, Amir Sarayani, Juan Hincapie-Castillo, Almut Winterstein

Description

The data include tables and figures that may interest the readership of the following article: Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States

Comparative Effectiveness of the iPLEDGE Program to Mitigate Teratogenic Risk of Isotretinoin in the United States: Supplementary Data

Description

Files

Categories

Licence